Neutra Life Sciences Expands Clinical Research Network with New Family Medicine Partnership

Neutra Corp's wholly owned subsidiary, Neutra Life Sciences, has expanded its clinical research footprint by securing a new clinical trial site partnership with MediNet Family Care Clinic, which specializes in Internal Medicine and Family Medicine. This strategic move aligns with the company's ongoing mission to grow its site management organization and bring high-quality, community-based research opportunities to diverse patient populations.

The new Internal Medicine/Family Medicine site is located in a high-traffic area near the border of Sugar Land and Houston and is led by an experienced research team with a strong background in conducting clinical trials and delivering consistent, quality data. The site is fully equipped to support a wide range of protocol designs, including Phase II and III studies focused on chronic conditions such as hypertension, diabetes, hyperlipidemia, and other prevalent therapeutic areas.

Sydney Jim, CEO of Neutra Corp, stated that this partnership represents another important step in the company's long-term strategy to grow organically and provide sponsors and contract research organizations with efficient, responsive, and high-performing research sites. By expanding into Internal Medicine and Family Medicine, the company is furthering its ability to support diverse protocols while continuing to meet the highest standards of patient care and data integrity.

Concurrently, Neutra Corp has engaged a dedicated Investor Relations Firm to strengthen communication and transparency with shareholders and the broader investment community. This strategic move underscores the company's commitment to building lasting investor confidence, enhancing market visibility, and providing timely, accurate insights into the company's growth, performance, and strategic direction. The experienced Investor Relations team aims to foster stronger partnerships with current and prospective investors as the company continues to expand operations and deliver long-term value.

Neutra Life Sciences continues to experience steady growth across multiple specialties, with plans to add additional therapeutic areas in the coming quarters. Each new site is carefully selected and supported to ensure optimal performance and alignment with sponsor and CRO expectations. With this expansion, Neutra Life Sciences is preparing to launch a new Diabetic Foot Ulcer trial at one of its brand-new sites in Sugar Land, Texas, demonstrating the practical application of its growing network capabilities.

The expansion into family medicine represents a significant development for clinical research accessibility, as primary care settings often serve as the first point of contact for patients with chronic conditions. This approach could potentially accelerate patient recruitment and improve the diversity of clinical trial participants, addressing long-standing challenges in clinical research. For more information about the company's operations, visit https://www.neutrainc.com.